Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Industry May Need To Inject More Funds Into R&D – GSK Exec

Executive Summary

Pharmaceutical manufacturers should consider increasing research & development investments to sustain growth, GlaxoSmithKline R&D Chairman Tachi Yamada declared during a Nov. 30 pipeline update

You may also be interested in...



Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D

Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said

Related Content

Topics

UsernamePublicRestriction

Register

PS046634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel